Spatial microbiome-metabolic crosstalk drives CD8+ T-cell exhaustion through the butyrate-HDAC axis in colorectal cancer
Frontiers in Microbiology · 08.12.2025 · 16
DOI: 10.3389/fmicb.2025.1704491 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 08.12.2025. Verfasst von Xiaoyang Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Medical and Health Development Foundation, Qingdao Community Charity Project.
Abstract (Originalsprache)
Background
The spatial organization of intratumoral microbiota and its metabolic impact on immunotherapy response in colorectal cancer (CRC) is unclear, limiting targeted interventions.
Methods
We integrated single-cell RNA-seq, spatial transcriptomics, and microbial multi-omics from a discovery cohort of 23 treatment-naïve CRC patients. Findings were validated in an independent validation cohort from The Cancer Genome Atlas (TCGA-CRC, n = 159).
Results
Spatial depletion of Streptococcus and Acetivibrio in tumor niches disrupts butyrate-histone deacetylase (HDAC) signaling, leading to programmed cell death 1 (PDCD1) hyperacetylation and CD8 + T-cell exhaustion. The Colorectal Cancer Microbiome Score (CMS) may serve as a predictive biomarker for immunotherapy response and HDAC inhibitor-based combination therapy. We developed the CMS, a spatial biomarker that stratifies patients by microbial-metabolic dysfunction, predicting immunotherapy resistance (e.g., higher tumor immune dysfunction and exclusion (TIDE) scores; p < 0.01) and guiding combinatorial HDAC inhibition for CMS-defined subgroups. In silico fecal microbiota transplantation (FMT) validated CMS as an actionable target for microbiota modulation. Butyrate supplementation in vitro restored HDAC activity and reduced PD-1 expression on CD8 + T cells, validating the proposed mechanism.
Conclusion
Our study unveils a spatially defined, microbiome-driven metabolic niche that epigenetically programs CD8 + T-cell exhaustion via the butyrate-HDAC axis, revealing a targetable mechanism to overcome immunotherapy resistance in CRC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China.
- Department of Surgery, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China.
- Department of Anesthesiology, Medical College of Jinzhou Medical University, Jinzhou, Liaoning, China.
- Huashan School of Medicine, Shanghai Medical College, Fudan University, Shanghai, China.
Förderung
- China Medical and Health Development Foundation
- Qingdao Community Charity Project
Zitieren
APA
Chen, X., Zhang, Y., Zhang, G., Wang, D., Dou, L., Wang, Y., Huang, Z., & Liu, X. (2025). Spatial microbiome-metabolic crosstalk drives CD8+ T-cell exhaustion through the butyrate-HDAC axis in colorectal cancer. Frontiers in Microbiology, 16. https://doi.org/10.3389/fmicb.2025.1704491
Vancouver
Chen X, Zhang Y, Zhang G, Wang D, Dou L, Wang Y, et al. Spatial microbiome-metabolic crosstalk drives CD8+ T-cell exhaustion through the butyrate-HDAC axis in colorectal cancer. Frontiers in Microbiology. 2025;16. doi:10.3389/fmicb.2025.1704491
BibTeX
@article{Chen2025,
author = {Chen, Xiaoyang and Zhang, Yinxu and Zhang, Guangyu and Wang, Dai and Dou, Linhua and Wang, Yuxi and Huang, Zining and Liu, Xiaomei},
title = {Spatial microbiome-metabolic crosstalk drives CD8+ T-cell exhaustion through the butyrate-HDAC axis in colorectal cancer},
journal = {Frontiers in Microbiology},
year = {2025},
volume = {16},
doi = {10.3389/fmicb.2025.1704491}
}
EUVIMED